interferon-gamma + nivolumab

Interferon-gamma + nivolumab is an investigational combination therapy consisting of two immunomodulatory agents. Interferon-gamma (IFN-γ) is a cytokine that activates immune cells and enhances antigen presentation, while nivolumab is a monoclonal antibody that inhibits the programmed cell death protein 1 (PD‑1) receptor on T cells, thereby blocking an immune checkpoint and promoting anti-tumor immunity. The combination aims to enhance anti-tumor responses by both stimulating immune activation through IFN‑γ and relieving PD‑1–mediated inhibition with nivolumab. This regimen has been studied in phase I clinical trials for patients with advanced or metastatic solid tumors who have progressed on prior therapies[1][4][5]. Early studies suggest the combination may be safe at certain doses, with most adverse events being low grade and associated primarily with interferon-gamma[1][4]. The approach seeks to leverage complementary mechanisms of action to improve outcomes over monotherapy.

Brand names

Opdivo (for nivolumab)Actimmune (for interferon gamma-1b)

Other names

IFN-gamma + nivolumabIFNγ + nivolumabInterferon gamma + Opdivo